Publication of new Aveed data in Journal of Clinical Pharmacology; data evaluates dosing flexibility in men with hypogonadism.
The objective of this population PK analysis was to assess the potential impact of a more frequent dose regimen of testosterone undecanoate (8 weeks vs. 10 weeks) on exposure parameters of clinical interest.
The current FDA-approved recommended dose of Aveed is 3 mL (750 mg) injected intermuscularly, followed by 3 mL (750 mg) injected after 4 weeks, then 3 mL (750 mg) injected every 10 weeks thereafter. The findings from this PK model and simulation were published in The Journal of Clinical Pharmacology.
See-"Population Pharmacokinetic Modeling and Simulations to Evaluate a Potential Dose Regimen of Testosterone Undecanoate in Hypogonadal Males."-Alexander W. Pastuszak MD, PhD, Mark Bush PhD, Laura Curd MS, Saji Vijayan MBBS, D.Diab, Tony Priestley PhD, Qinfang Xiang PhD, Yiqun Hu MD, PhD First published: 16 July 2021 https://doi.org/10.1002/jcph.1939.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins